Leaving an Imprint

Among the first to discover epigenetic reprogramming during mammalian development, Wolf Reik has been studying the dynamics of the epigenome for 30 years.

Written byAnna Azvolinsky
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

WOLF REIK
Associate Director of Research, Babraham Institute, Cambridge, U.K. Professor of Epigenetics, University of Cambridge Associate Faculty, Sanger Institute
THE BARBRAHAM INSTITUTE
As a medical school student at the University of Hamburg in 1982, Wolf Reik heard a lecture by Rudolf Jaenisch on how retroviruses could be used in transgenic mice to probe gene expression during development. “I became totally electrified sitting in this lecture,” says Reik. “I thought, ‘This is the thing I must do.’” Medical schools in Germany at the time required a thesis project for graduation, but not necessarily several years of laboratory work; nonetheless, Reik decided he wanted the experience of working in a lab, something he’d only had a taste of before. “I had already started in a couple of laboratories, but I would get bored and leave after a few days. The first was a neurobiology lab. Because I had a great interest in literature and language, I thought neurobiology would be really exciting. But when I started, it was just incredibly dull.” Listening to Jaenisch changed all that.

But despite Reik’s enthusiasm, Jaenisch turned him down. “He told me he didn’t want any medics [in his lab]. He knew full well what he was talking about, since he was a medic himself. I think he thought medical students thought PhD research was a sideline that they didn’t take too seriously.” In the end, Reik’s persistence managed to persuade Jaenisch to take him on. “Maybe it’s because I just wouldn’t leave,” he says.

“In the mammalian field, the imprinting field, together with the X-inactivation field, was the birthplace of epigenetics.”

Reik found he enjoyed doing hands-on experiments. Jaenisch’s lab (which has since moved to the Whitehead Institute) had already demonstrated a link between de novo methylation in the mouse embryo genome and inhibition of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • head shot of blond woman wearing glasses

    Anna Azvolinsky received a PhD in molecular biology in November 2008 from Princeton University. Her graduate research focused on a genome-wide analyses of genomic integrity and DNA replication. She did a one-year post-doctoral fellowship at Memorial Sloan Kettering Cancer Center in New York City and then left academia to pursue science writing. She has been a freelance science writer since 2012, based in New York City.

    View Full Profile

Published In

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas